A Young Patient with Recurrent Respiratory Tract Infection and Anasarca

Overview

Journal BMJ Case Rep

Specialty General Medicine

Date 2013 Nov 13

PMID 24217929

Authors

Kosar Hussain

Niaz Ahmed Shaikh

Liza Thomas

Mahmoud M Marashi

Affiliations

Soon will be listed here.

Abstract

A young man with a history of recurrent respiratory tract infections for the past 8 years presented with generalised anasarca. He was found to have advanced renal disease (stage 4) and a profound proteinuria of 82.9 g/day. Further workup revealed the presence of advanced bronchiectatic changes in the lungs. Rectal biopsy showed the characteristic pattern of amyloid deposition. A diagnosis of systemic amyloidosis secondary to bronchiectasis was made. To the best of our knowledge no other cases of bronchiectasis-associated renal amyloid disease with such marked proteinuria have been reported in the literature. Our patient had a relatively short duration between the onset of his symptoms related to underlying bronchiectasis and his clinical presentation of renal amyloidosis. He had an aggressive course of disease and unfortunately died at a very young age.

References

Gillmore J, Lovat L, Persey M, Pepys M, Hawkins P . Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001; 358(9275):24-9. DOI: 10.1016/S0140-6736(00)05252-1. View

Rikitake O, Sakemi T, Yoshikawa Y, Nagano Y, Watanabe T . Adult Fanconi syndrome in primary amyloidosis with lambda light-chain proteinuria. Jpn J Med. 1989; 28(4):523-6. DOI: 10.2169/internalmedicine1962.28.523. View

Samuels M, Thompson N, Leichty D, Ridgway E . Amyloid goiter in cystic fibrosis. Thyroid. 1995; 5(3):213-5. DOI: 10.1089/thy.1995.5.213. View

Villa F, Dionigi G, Tanda M, Rovera F, Boni L . Amyloid goiter. Int J Surg. 2009; 6 Suppl 1:S16-8. DOI: 10.1016/j.ijsu.2008.12.025. View

Nakae H, Endo S, Inada K, Takakuwa T, Kasai T, Yoshida M . Serum complement levels and severity of sepsis. Res Commun Chem Pathol Pharmacol. 1994; 84(2):189-95. View

Gertz M, Kyle R . Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore). 1991; 70(4):246-56. View

Turgut F, Kanbay M, Kaya A, Uz B, Akcay A . Bilateral renal artery embolization in a case with severe proteinuria secondary to amyloidosis in a hemodialysis patient. Amyloid. 2007; 14(2):157-8. DOI: 10.1080/13506120701259812. View

Dember L . Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006; 17(12):3458-71. DOI: 10.1681/ASN.2006050460. View

Joss N, McLaughlin K, Simpson K, Boulton-Jones J . Presentation, survival and prognostic markers in AA amyloidosis. QJM. 2000; 93(8):535-42. DOI: 10.1093/qjmed/93.8.535. View

10.

Ozdemir B, Ozdemir F, Sezer S, Sar A, Haberal M . Among therapy modalities of end-stage renal disease, renal transplantation improves survival in patients with amyloidosis. Transplant Proc. 2006; 38(2):432-4. DOI: 10.1016/j.transproceed.2005.12.051. View

11.

Perfetto F, Moggi-Pignone A, Livi R, Tempestini A, Bergesio F, Matucci-Cerinic M . Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol. 2010; 6(7):417-29. DOI: 10.1038/nrrheum.2010.84. View

12.

Akcay S, Akman B, Ozdemir H, Eyuboglu F, Karacan O, Ozdemir N . Bronchiectasis-related amyloidosis as a cause of chronic renal failure. Ren Fail. 2002; 24(6):815-23. DOI: 10.1081/jdi-120015683. View

13.

Stratta P, Gravellone L, Cena T, Rossi D, Gaidano G, Fenoglio R . Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: a single center experience. Crit Rev Oncol Hematol. 2010; 79(1):31-42. DOI: 10.1016/j.critrevonc.2010.05.001. View

14.

Sherif A, Refaie A, Sobh M, Mohamed N, Sheashaa H, Ghoneim M . Long-term outcome of live donor kidney transplantation for renal amyloidosis. Am J Kidney Dis. 2003; 42(2):370-5. DOI: 10.1016/s0272-6386(03)00676-0. View

15.

Goldsmith D, Roberts I, Short C, Mallick N . Complete clinical remission and subsequent relapse of bronchiectasis-related (AA) amyloid induced nephrotic syndrome. Nephron. 1996; 74(3):572-6. DOI: 10.1159/000189454. View

16.

Dember L, Hawkins P, Hazenberg B, Gorevic P, Merlini G, Butrimiene I . Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007; 356(23):2349-60. DOI: 10.1056/NEJMoa065644. View

17.

Lachmann H, Goodman H, Gilbertson J, Gallimore J, Sabin C, Gillmore J . Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007; 356(23):2361-71. DOI: 10.1056/NEJMoa070265. View

18.

Rocken C, Shakespeare A . Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch. 2002; 440(2):111-122. DOI: 10.1007/s00428-001-0582-9. View